Date: 2016-01-15
Type of information: Termination of an agreement
Compound: compounds targeting Bromodomain and Extra-Terminal (BET) proteins
Company: Medivation (USA - MA) OncoFusion Therapeutics (USA - MI)
Therapeutic area: Cancer - Oncology
Type agreement: R&D licensing
Action mechanism: BET bromodomain inhibitor. BET bromodomain proteins regulate gene expression and have been shown to play a critical role in cancer and other diseases. Emerging research in the area of cancer biology suggests that targeting epigenetic regulators such as the bromodomain family of proteins may reduce the growth of a number of tumor types including certain hematological and solid tumors.
Disease:
Details: * On April 23, 2014, Medivation and OncoFusion Therapeutics announced that they have entered into a research and license agreement for certain compounds targeting Bromodomain and Extra-Terminal (BET) proteins for potential use in oncology and other disease areas. Medivation will gain exclusive worldwide rights for the development and commercialization of these compounds. Under the terms of the agreement, Medivation shall have access to OncoFusion's growing library of small molecule BET bromodomain inhibitor compounds from which Medivation may select compounds to move forward into drug development efforts.
Financial terms: OncoFusion is eligible to receive undisclosed upfront payments and potential future milestone payments subject to achievement of defined clinical and commercial milestone events. In addition, OncoFusion shall be eligible to receive royalties on the commercial sale of approved products as defined in the agreement. Further financial details were not disclosed.
Latest news: * On January 15, 2016, OncoFusion Therapeutics announced that it has reached an agreement with Medivation to reacquire the rights to certain compounds targeting Bromodomain and Extra-Terminal (BET) proteins identified and developed under a research and license agreement announced between the parties in April 2014. OncoFusion plans to advance development into clinical trials. As a selective inhibitor of BET bromodomain proteins, if it is ultimately approved for marketing, such a compound could provide a treatment for a wide range of cancers including castrate-resistant prostate cancer.
